Process chemistry paper Angelini-Enantia

Process chemistry paper Angelini-Enantia

News

Home > News > Barcelona Science Park’s 20th anniversary
BarcelonaScienceParks20thanniversary

New Process Chemistry paper in collaboration with Angelini Pharma

A new paper has been published on the process chemistry work that Enantia and italian Angelini Pharma have done together.

Within this collaboration, a new robust and scalable synthetic route to obtain calcium acamprosate has been developed. The selective precipitation of calcium acamprosate as an easily filterable solid with 74–77% yield was achieved by the one-pot nucleophilic opening of 1,3-propanesultone with potassium acetamide, following by cation exchange with calcium ion at controlled pH.

In comparison with other procedures described in the literature and used previously, the newly developed and optimized methodology gives rise to a remarkably more efficient and direct synthesis of calcium acamprosate, avoiding the use of toxic chemicals and multistep synthesis.

This is a perfect example of how our process chemistry team can support our customers in designing and optimizing new routes of synthesis, leading to procedures that can be easily scaled up and used later at industrial scale. Furthermore, this type of projects can be complemented at Enantia by performing the carry-over of the impurities, and the characterization thereof.

 

You can read the full paper here.

Enantia at Future Cannabis Strategies Europe 2020

Enantia at Future Cannabis Strategies Europe 2020

News

Home > News > Enantia celebrates its 15th anniversary
Enantiacelebratesits15thanniversary

Enantia at Future Cannabis Strategies Europe 2020

January 17th, 2019

Our CEO Dr. Joan Feixas will be attending the Future Cannabis Strategies Europe 2020, taking place in Royal Lancaster London on the 29th and 30th of January, 2020.

During the event, we will be discussing with key partners and customers about our Cannabinoids Cocrystal Platform, which enables the manufacturing of a wide range of cannabinoids, both from natural and synthetic origin.

As part of this platform, Enantia is already developing commercial batches of API grade cGMP Cannabidiol (CBD), along with minor cannabinoids such as Cannabidivarin (CBDV), Cannabigerol (CBG), Cannabichromene (CBC) and Cannabinol (CBN).

If you are interested in our very high-quality cannabinoids, or if you are looking for a cost-effective purification technology for your cannabis extracts, do not hesitate to contact us to organize a meeting.

New Medicinal Chemistry paper in collaboration with Esteve Pharmaceuticals

New Medicinal Chemistry paper in collaboration with Esteve Pharmaceuticals

News

Home > News > Barcelona Science Park’s 20th anniversary

BarcelonaScienceParks20thanniversary

New Medicinal Chemistry paper in collaboration with Esteve Pharmaceuticals

The Journal of Medicinal Chemistry has recently published some of the results obtained in our Medicinal Chemistry collaboration with Esteve Pharmaceuticals, aimed at the identification of novel dual ligands of the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR), as part of Esteve’s RD activity to develop new, potent and safer analgesics.

The chemistry work, which was carried out by Enantia’s Medicinal Chemistry team led by Dr. Marina Virgili, started with the design of the spirocyclic morpholino-piperidine core using rational drug design strategies. The efficient synthetic approach developed, allowed then for the rapid preparation of analogues with diversification in several positions of the scaffold, rendering the promising Lead described in this paper. The subsequent Lead Optimization program led to the discovery of a clinical candidate, whose identification will be reported soon.

Enantia has a long track record in Medicinal Chemistry services to the pharmaceutical industry, with more than 20 patents related to this activity, which includes the design and synthesis of new scaffolds and libraries of small molecules with potential biological activity.

In addition to conventional MedChem activities such as Hit-to-Lead and Lead Optimization programs, Structure-Activity Relationship (SAR) and Drug Metabolism and Pharmacokinetics (DMPK) interpretation, Enantia can also collaborate in the early stages of the drug development process by preparing cold labelled compounds and metabolites of a given candidate, as well as by identifying its best solid form in our Solid State department.

You can read the full paper here.

Merry Christmas and prosperous 2020!

Merry Christmas and prosperous 2020!

News

Home > News > Season’s greetings 2019
merrychrismasenantia

Merry Christmas and prosperous 2020!

December 17th, 2019

Special greetings at Christmas time to express our sincere thanks to everyone that has placed their confidence and loyalty to Enantia and has made this successful year possible.

Thanks to all our customers, employees, and suppliers, we wish you merry Christmas and a happy and prosperous 2020!

 

Enantia supports an environmental-friendly paper-free holiday season.

Biofit 2019

Biofit 2019

News

Home > News > Enantia at Biofit 2018
EnantiaatBiofit2018

Enantia at Biofit 2019

December 13th, 2019

 

On December 10th and 11th Marseille hosted the 8th Biofit event for big pharma, biotech companies, CROs and public research institutes.

On this edition, Enantia was selected to participate in the Service pitch session, in which we presented our state-of-the-art cocrystallization technology that enables selective, scalable and affordable purification processes of substances in complex mixtures.

We had the chance to strength former collaborations and to foster new networks. Thanks to everyone who came along.

Enantia attended the 30th edition of the CPhI Worldwide 2019

Enantia attended the 30th edition of the CPhI Worldwide 2019

News

Home > News > Enantia attended the 30th edition of the CPhI Worldwide 2019

Enantia CPHI 2019

Enantia at the 30th edition of the CPhI Worldwide 2019

November 19th, 2019

Enantia attended the 30th edition of the CPhI Worldwide 2019 event that took place in Frankfurt (Germany) from the 5th to the 7th of November.

Thanks to everyone for the interesting meetings.

We had the chance to discuss not only our services in chemical discovery and development, but also our cannabinoids cocrystal platform and the minor cannabinoids that we offer (CBDV, CBG, CBC, CBN).

We hope to meet you all very soon.

Enantia’s cannabidiol cocrystal highlighted in Chemistry World

Enantia’s cannabidiol cocrystal highlighted in Chemistry World

News

Home > News > Enantia’s cannabidiol cocrystal highlighted in Chemistry World

1_enantias_cannabidol

Enantia’s cannabidiol cocrystal highlighted in Chemistry World

March 26th, 2019

We are pleased to share this article from Chemistry World about Enantia’s cocrystalisation technology.

Enantia has developed new cannabidiol (CBD) cocrystals that allow CBD purification from complex mixtures, either natural or synthetic.

You can read the article here.

Enantia announces its Cannabinoids Cocrystal Platform

Enantia announces its Cannabinoids Cocrystal Platform

News

Home > News > Enantia announces its Cannabinoids Cocrystal Platform

enantia-announces-its-cannabinoids-cocrystal-platform

Enantia announces its Cannabinoids Cocrystal Platform

« Enantia has developed new cannabinoid cocrystals to allow their purification from complex mixtures (natural and synthetic) and to obtain improved active pharmaceutical ingredients and drug formulations. »

March 6th, 2019

Enantia has again succeeded in applying cocrystallisation technology to a new family of compounds, the cannabinoids.

Cannabinoids, especially cannabidiol (CBD) and tetrahydrocannabinol (THC), are known by their ability to interact with the endocannabinoid system, which play an important role in a number of biochemical pathways. Besides Sativex® and Epidiolex®, the only two approved drugs containing CBD, the potential of cannabinoids to be used to treat a large number of medical conditions is very high as is shown by the number of ongoing clinical trials. In addition, the changes in the laws that regulate the use of cannabis in different countries are fostering the use of cannabinoids in areas like medical cannabis, food and cosmetics, to mention a few.
 
Enantia has been working to apply cocrystallisation technology to cannabinoids with two objectives: to develop a highly efficient purification process from either natural or synthetic sources, and to obtain improved solid forms of different cannabinoids, notably CBD and THC, to be used as pharmaceutical actives.
 
This research led us to the discovery of new cocrystals of CBD (see our first published patent application of February 2019, WO2019/030158 A1) and the corresponding processes to prepare them. These cocrystals allow the purification of CBD (either from crude cannabis extracts or synthetic mixtures) with a simple, cost-effective and industrial scalable process. Furthermore, these new cocrystals can also be used as pharmaceutical ingredients in drug formulations.
 
Enantia is open to discuss with possible partners the licensing of this technology for different uses. Expressions of interest can be directed to Joan Feixas, Enantia’s CEO.
 

Merry Christmas and happy new year!

Merry Christmas and happy new year!

News

Home > News > Merry Christmas and happy new year!
merrychrismasenantia

Merry Christmas and happy new year!

December 17th, 2018

We would like to wish all our customers, collaborators and friends, happy holidays and the best wishes for 2019!

Enantia at Biofit 2018

Enantia at Biofit 2018

News

Home > News > Enantia at Biofit 2018
EnantiaatBiofit2018

Enantia at Biofit 2018

November 30th, 2018

We will be at Biofit from the 3rd to the 5th of December in Lille, France.
If you want to know more about our services in solid form and organic synthesis (both chiral and achiral) contact us at in info@enantia.com to organize a meeting.